Future directions in the treatment of osteosarcoma

Michael W. Bishop, Katherine A. Janeway, Richard Gorlick

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Purpose of review Overall survival rates for osteosarcoma have remained essentially unchanged over the past 3 decades despite attempts to improve outcome via dose intensification and modification based on response. This review describes recent findings from contemporary clinical trials, advances in the comprehension of osteosarcoma biology and genomic complexity, and potential opportunities using targeted and immune-mediated therapies. Recent findings Recent results from international collaborative trials have failed to demonstrate an ability to improve outcomes using a design in which the randomized question is dictated based on histologic response to preoperative chemotherapy. Novel prognostic markers assessable at diagnosis are vital to identifying subsets of osteosarcoma. Clinical trials focus has now shifted to serial phase II studies of novel agents to evaluate for activity in recurrent and refractory disease. In-depth analyses have revealed profound genomic instability and heterogeneity across patients, with nearly universal TP53 aberration. Although driver mutational events have not clearly been established, frequent derangements in specific pathways may suggest opportunities for therapeutic exploitation. Genomic complexity may lend support to a role for immune-mediated therapies. Summary Rigorous preclinical investigations are potentially generating novel strategies for the treatment of osteosarcoma that will inform the next generation of clinical trials, with the opportunity to identify agents that will improve survival outcomes.

Original languageEnglish (US)
Pages (from-to)26-33
Number of pages8
JournalCurrent Opinion in Pediatrics
Volume28
Issue number1
DOIs
StatePublished - Feb 1 2016

Fingerprint

Osteosarcoma
Clinical Trials
Aptitude
Genomic Instability
Therapeutics
Survival Rate
Drug Therapy
Survival
Direction compound

Keywords

  • genomic complexity
  • immunotherapy
  • osteosarcoma
  • targeted therapy
  • TP53

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Future directions in the treatment of osteosarcoma. / Bishop, Michael W.; Janeway, Katherine A.; Gorlick, Richard.

In: Current Opinion in Pediatrics, Vol. 28, No. 1, 01.02.2016, p. 26-33.

Research output: Contribution to journalArticle

Bishop, Michael W. ; Janeway, Katherine A. ; Gorlick, Richard. / Future directions in the treatment of osteosarcoma. In: Current Opinion in Pediatrics. 2016 ; Vol. 28, No. 1. pp. 26-33.
@article{f16ff1618a5b4ecfa6347617ad8e26a6,
title = "Future directions in the treatment of osteosarcoma",
abstract = "Purpose of review Overall survival rates for osteosarcoma have remained essentially unchanged over the past 3 decades despite attempts to improve outcome via dose intensification and modification based on response. This review describes recent findings from contemporary clinical trials, advances in the comprehension of osteosarcoma biology and genomic complexity, and potential opportunities using targeted and immune-mediated therapies. Recent findings Recent results from international collaborative trials have failed to demonstrate an ability to improve outcomes using a design in which the randomized question is dictated based on histologic response to preoperative chemotherapy. Novel prognostic markers assessable at diagnosis are vital to identifying subsets of osteosarcoma. Clinical trials focus has now shifted to serial phase II studies of novel agents to evaluate for activity in recurrent and refractory disease. In-depth analyses have revealed profound genomic instability and heterogeneity across patients, with nearly universal TP53 aberration. Although driver mutational events have not clearly been established, frequent derangements in specific pathways may suggest opportunities for therapeutic exploitation. Genomic complexity may lend support to a role for immune-mediated therapies. Summary Rigorous preclinical investigations are potentially generating novel strategies for the treatment of osteosarcoma that will inform the next generation of clinical trials, with the opportunity to identify agents that will improve survival outcomes.",
keywords = "genomic complexity, immunotherapy, osteosarcoma, targeted therapy, TP53",
author = "Bishop, {Michael W.} and Janeway, {Katherine A.} and Richard Gorlick",
year = "2016",
month = "2",
day = "1",
doi = "10.1097/MOP.0000000000000298",
language = "English (US)",
volume = "28",
pages = "26--33",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Future directions in the treatment of osteosarcoma

AU - Bishop, Michael W.

AU - Janeway, Katherine A.

AU - Gorlick, Richard

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Purpose of review Overall survival rates for osteosarcoma have remained essentially unchanged over the past 3 decades despite attempts to improve outcome via dose intensification and modification based on response. This review describes recent findings from contemporary clinical trials, advances in the comprehension of osteosarcoma biology and genomic complexity, and potential opportunities using targeted and immune-mediated therapies. Recent findings Recent results from international collaborative trials have failed to demonstrate an ability to improve outcomes using a design in which the randomized question is dictated based on histologic response to preoperative chemotherapy. Novel prognostic markers assessable at diagnosis are vital to identifying subsets of osteosarcoma. Clinical trials focus has now shifted to serial phase II studies of novel agents to evaluate for activity in recurrent and refractory disease. In-depth analyses have revealed profound genomic instability and heterogeneity across patients, with nearly universal TP53 aberration. Although driver mutational events have not clearly been established, frequent derangements in specific pathways may suggest opportunities for therapeutic exploitation. Genomic complexity may lend support to a role for immune-mediated therapies. Summary Rigorous preclinical investigations are potentially generating novel strategies for the treatment of osteosarcoma that will inform the next generation of clinical trials, with the opportunity to identify agents that will improve survival outcomes.

AB - Purpose of review Overall survival rates for osteosarcoma have remained essentially unchanged over the past 3 decades despite attempts to improve outcome via dose intensification and modification based on response. This review describes recent findings from contemporary clinical trials, advances in the comprehension of osteosarcoma biology and genomic complexity, and potential opportunities using targeted and immune-mediated therapies. Recent findings Recent results from international collaborative trials have failed to demonstrate an ability to improve outcomes using a design in which the randomized question is dictated based on histologic response to preoperative chemotherapy. Novel prognostic markers assessable at diagnosis are vital to identifying subsets of osteosarcoma. Clinical trials focus has now shifted to serial phase II studies of novel agents to evaluate for activity in recurrent and refractory disease. In-depth analyses have revealed profound genomic instability and heterogeneity across patients, with nearly universal TP53 aberration. Although driver mutational events have not clearly been established, frequent derangements in specific pathways may suggest opportunities for therapeutic exploitation. Genomic complexity may lend support to a role for immune-mediated therapies. Summary Rigorous preclinical investigations are potentially generating novel strategies for the treatment of osteosarcoma that will inform the next generation of clinical trials, with the opportunity to identify agents that will improve survival outcomes.

KW - genomic complexity

KW - immunotherapy

KW - osteosarcoma

KW - targeted therapy

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=84954026712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954026712&partnerID=8YFLogxK

U2 - 10.1097/MOP.0000000000000298

DO - 10.1097/MOP.0000000000000298

M3 - Article

C2 - 26626558

AN - SCOPUS:84954026712

VL - 28

SP - 26

EP - 33

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 1

ER -